Search Within

Joachim Yahalom

  1. "Steven Horwitz"
Formats
  1. Meeting Abstract (33)
  2. Journal Article (31)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (65)
  2. Department of Medicine (65)
  3. Hematologic Malignancies, Division of (65)
  4. Lymphoma (65)
  5. Population Sciences Research Program (65)
  6. Radiation Oncology, Department of (65)

More Groups

People
  1. Steven Horwitz (65)
  2. Andrew Zelenetz (60)
  3. Ariela Noy (45)
  4. Alison Moskowitz (44)
  5. David Straus (44)
  6. Paul Hamlin (44)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (5)
  4. 2022 (3)
  5. 2021 (6)
  6. 2020 (7)

More Years

Publications
  1. Blood (25)
  2. Journal of the National Comprehensive Cancer Network (9)
  3. Hematological Oncology (6)
  4. Journal of Clinical Oncology (6)
  5. British Journal of Haematology (4)
  6. Blood Advances (3)

More Publications

Publishers
  1. American Society of Hematology (28)
  2. Harborside Press (9)
  3. American Society of Clinical Oncology (6)
  4. Wiley Blackwell (6)
  5. John Wiley & Sons (4)
  6. Elsevier Inc. (3)

More Publishers

Results (65)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Treatment of vulvar mycosis fungoides tumors with localized radiotherapy
    Journal Article

    Geller, S.; Pitter, K.; Moskowitz, A.; Horwitz, S. M.; Yahalom, J.; Myskowski, P. L.
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017
    Journal Article

    Wierda, W. G.; Zelenetz, A. D.; Gordon, L. I.; Abramson, J. S.; Advani, R. H.; Andreadis, C. B.; Bartlett, N.; Byrd, J. C.; Caimi, P.; Fayad, L. E.; more...
    Journal of the National Comprehensive Cancer Network (2017)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population
    Journal Article

    Qi, S.; Yahalom, J.; Hsu, M.; Chelius, M.; Lunning, M.; Moskowitz, A.; Horwitz, S.
    Leukemia and Lymphoma (2016)

    Fulltext@MSK | Save
  • NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016: Featured updates to the NCCN guidelines
    Journal Article

    Horwitz, S. M.; Zelenetz, A. D.; Gordon, L. I.; Wierda, W. G.; Abramson, J. S.; Advani, R. H.; Andreadis, C. B.; Bartlett, N.; Byrd, J. C.; Fayad, L. E.; more...
    Journal of the National Comprehensive Cancer Network (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save